ClinicalTrials.gg
Active, not recruitingNCT06711107Updated Apr 10, 2025

Predicting NOM Failure in Bowel Obstruction

An observational study in Small Bowel Obstruction and Intestinal Pseudo-Obstruction, sponsored by Centre Hospitalier Universitaire de Nice. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by Centre Hospitalier Universitaire de Nice · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
370
Ages
18 Years and older
Sex
All
01

Study summary

"This study aims to collect data on patients with small bowel obstruction (SBO) admitted to hospitals in France and Italy from May 2022 to October 2024 to develop a deep convolutional neural network (DCNN) model. This model will analyze anonymized CT scans to assess the effectiveness of non-operative management (NOM) for SBO, supporting decisions on surgical intervention. Eligible patients are those diagnosed with SBO due to abdominal adhesions who initially received NOM for at least 24 hours. Patients with other SBO causes, early surgery within 24 hours, or those without a CT scan diagnosis are excluded.

Data collection spans hospitals in Antibes, Nice, Milan, and Vimercate, targeting consecutive SBO cases with adhesive etiology. To perform an external validation of the DCNN, data will also be retrospectively collected from patients admitted to the Antibes hospital between May 2021 and April 2022 with adhesive SBO. This validation set includes patients who underwent NOM successfully and those who needed surgery after NOM failure. The DCNN model will be applied to anonymized, non-contrast and contrast-enhanced portal-phase CT scans of these patients, with researchers blinded to each patient's NOM outcome to prevent bias. The model's performance will then be evaluated using accuracy metrics consistent with those used in initial model testing, ensuring the reliability of results when applied to external cases.

NOM, after adhesive SBO diagnosis via clinical exams, blood tests, and CT scans, includes fasting, analgesics, antiemetics, and fluids as per current guidelines, without necessarily using nasogastric tubes or contrast agents. Patients are re-evaluated after 24 hours to determine whether NOM should continue or if surgery is necessary. NOM is deemed effective if patients experience symptom resolution, stool passage, and no recurrence within 90 days. NOM failure is defined by the need for laparoscopic or laparotomic surgery, based on symptoms' persistence, worsening, or radiological indicators of blockage despite adequate NOM.

Data collection, registered with the French National Committee for Data Protection, includes variables like age, sex, medical history, symptoms, blood tests, CT-scan findings, NOM details, and surgical information. Radiological data, including Digital Imaging and Communication in Medicine (DICOM) files of CT scans, will be anonymized and converted to the Neuroimaging Informatics Technology Initiative (NIfTI) format for secure storage and analysis.

The NIfTI data files will be randomly split into training and test datasets in an 80%-20% ratio, processed separately for non-contrast and contrast-enhanced CT scans. Data augmentation, including random rotation, flipping, zooming, translation, and noise addition, will be applied to improve model accuracy and reduce overfitting. Different DCNN models will be trained and tested and furtherly undergo external validation to produce a tool capable of predicting NOM failure and need for surgery in patients with adhesive SBO."

02

Conditions studied

  • Small Bowel Obstruction
  • Intestinal Pseudo-Obstruction
03

In context

Intestinal Pseudo-Obstruction

26 studies on the registry are indexed under Intestinal Pseudo-Obstruction; 6 are open to participants now.

Browse Intestinal Pseudo-Obstruction studies →

Lead sponsor

Centre Hospitalier Universitaire de Nice is the lead sponsor of 723 studies on the registry; 176 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The team will collect data from consecutive patients admitted to the Digestive Surgery Department of the Hospital of Antibes (Centre Hospitalier d'Antibes Juan-les-Pins, France) from May the 1st 2022 to October the 31st 2024, to the Digestive and Emergency Surgery Department (Nice University Hospital , France) from the 1st of May 2022 to the 31st of October 2024 , to the General Surgery and Trauma Center of the University Hospital Niguarda in Milan (Grande Ospedale Metropolitano Niguarda, Italy) from the 1st of May 2023 and the 31st of October 2024, and to the General Surgery Department of the Vimercate Hospital (Ospedale di Vimercate, Italy) from the 1st of May 2023 and the 31st of October 2024 with the diagnosis of SBO. Moreover, to perform external validation of the DCNN model, the team will collect data of patients admitted to the Digestive Surgery Department of the Antibes Juan-les-Pins hospital from the 1st of May 2021 to the 30th of April 20

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SBO diagnosed through clinical evaluation, blood tests, and an abdominal CT-scan performed at the admission in the Emergency Department.
  • SBO secondary to single or multiple abdominal adhesions.
  • Initial treatment of SBO by NOM for at least 24 hours.
  • Non-opposition to the anonymous data processing by the included patients."

Exclusion criteria

Exclusion Criteria:

  • admission for SBO other than of adhesive etiology (hernias, bowel or other abdominal neoplasms, foreign bodies, functional obstruction, etc.).
  • surgical treatment of SBO within 24 hours from admission or rather NOM duration \< 24 hours.
  • SBO diagnosis performed without CT-scan."
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
370 participants (actual)
Patient registry
No

Groups and cohorts

  • SBO patients

    "After adhesive SBO diagnosis is performed through clinical examination, blood tests, and abdominal CT-scan, and need for urgent surgical exploration excluded, patients are admitted to the General/Digestive Surgery Department for NOM. NOM consists in fasting, analgesics, antiemetics, and fluids administration, with or without electrolytes correction. Nasogastric tube positioning and/or hyperosmolar water-soluble contrast administration is not deemed necessary for the patient to be included in this study, thus allowing us to evaluate different management strategies for adhesive SBO. After at least 24 hours of NOM, patients are re-evaluated for NOM prosecution or surgical treatment. NOM is considered effective when patients achieved symptoms remission, flatus and stools evacuation, and realimentation without symptoms recurrence for at least 90 days. NOM failure is defined as need for surgery, both laparoscopic or laparotomic, to treat adhesive SBO. Surgical management depends on single

06

What researchers measure

Primary outcomes

  1. Performance of Deep Learning model in predicting NOM failure

    To measure the degree of agreement between the prediction made by the Deep Learning model and the actual success or failure of non-operative management for small bowel obstruction in the real situation. This will be measured through Area Under the Receiver Operator Characteristic curve (AUROC) assesment. AUROC varies between 0.5 and 1, corresponding to no class separation capacity and full class separation capacity, respectively.

    Time frame: 90 days from patients hospital discharge.

Secondary outcomes

  1. Performance evaluation: accuracy

    The number of true positives and true negatives among all predictions. It varies between 0 (no correct prediction) to 1 (full correct predictions).

    Time frame: 90 days from patients hospital discharge.

  2. Performance evaluation: precision

    The number of true positives divided by all the positive predictions (true positives and false positives). It varies between 0 (no correct prediction) to 1 (full correct predictions)

    Time frame: 90 days from patients hospital discharge.

  3. Performance evaluation: recall

    The number of true positives divided by the actual positive instances in the dataset (true positives and false negatives). It varies between 0 (no correct prediction) to 1 (full correct predictions).

    Time frame: 90 days from patients hospital discharge.

  4. Performance evaluation : balanced accuracy

    the aritmethic mean of sensitivity and specificity. It varies between 0 (no correct prediction) to 1 (full correct predictions).

    Time frame: 90 days from patients hospital discharge.

  5. Performance evaluation:F1-score

    It combines precision and recall. It ranges from 0-100%, and a higher F1 score denotes a better quality classifier.

    Time frame: 90 days from patients hospital discharge.

  6. Performance evaluation: Confusion matrix

    A visual representation of true positives, false positives, true negatives, and false negatives. It is depicted through a table.

    Time frame: 90 days from patients hospital discharge.

  7. Performance evaluation :Log-loss

    It indicates how close the prediction probability is to the corresponding actual/true value (0 or 1 in case of binary classification). The more the predicted probability diverges from the actual value, the higher is the log-loss value.

    Time frame: 90 days from patients hospital discharge.

  8. Performance evaluation: Cohen's Kappa

    A metric used to measure the level of agreement between two raters which can be a useful tool to gauge the performance of a classification model. It accounts for the fact that the raters may happen to agree on some items purely by chance. It varies between 0 (no correct prediction) to 1 (full correct predictions).

    Time frame: 90 days from patients hospital discharge.

07

Study locations

1 site
  • Andrea CHIERICI
    Nice, 06000, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06711107
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Jan 1, 2025
Primary completion
Feb 1, 2025
Completion
Apr 1, 2026 (estimated)
Last update
Apr 10, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion